Insider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 14,884 Shares of Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Sophia Randolph sold 14,884 shares of the business’s stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $36.77, for a total value of $547,284.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sophia Randolph also recently made the following trade(s):

  • On Monday, October 11th, Sophia Randolph sold 7,387 shares of ALX Oncology stock. The stock was sold at an average price of $60.97, for a total value of $450,385.39.
  • On Friday, September 10th, Sophia Randolph sold 7,387 shares of ALX Oncology stock. The stock was sold at an average price of $77.66, for a total value of $573,674.42.

ALXO opened at $36.32 on Thursday. ALX Oncology Holdings Inc. has a fifty-two week low of $34.98 and a fifty-two week high of $117.45. The firm has a market capitalization of $1.47 billion, a P/E ratio of -19.53 and a beta of 3.07. The stock’s fifty day moving average price is $61.99.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, November 11th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.13). Analysts predict that ALX Oncology Holdings Inc. will post -1.91 earnings per share for the current fiscal year.

A number of equities analysts have commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, August 18th. Piper Sandler reduced their price objective on shares of ALX Oncology from $97.00 to $85.00 and set an “overweight” rating for the company in a research report on Tuesday, November 9th. Lifesci Capital reaffirmed an “outperform” rating on shares of ALX Oncology in a research report on Thursday, November 4th. Zacks Investment Research cut shares of ALX Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, November 16th. Finally, Stifel Nicolaus assumed coverage on shares of ALX Oncology in a research report on Wednesday, September 29th. They set a “buy” rating and a $106.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $95.86.

A number of hedge funds have recently bought and sold shares of the stock. Credit Suisse AG raised its stake in ALX Oncology by 6.6% in the third quarter. Credit Suisse AG now owns 4,378 shares of the company’s stock valued at $324,000 after purchasing an additional 271 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in ALX Oncology by 7.5% in the third quarter. State Board of Administration of Florida Retirement System now owns 4,293 shares of the company’s stock valued at $317,000 after purchasing an additional 300 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in ALX Oncology by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 10,155 shares of the company’s stock valued at $555,000 after purchasing an additional 319 shares in the last quarter. Strs Ohio acquired a new position in ALX Oncology in the third quarter valued at about $36,000. Finally, Rafferty Asset Management LLC raised its stake in ALX Oncology by 1.2% in the second quarter. Rafferty Asset Management LLC now owns 43,721 shares of the company’s stock valued at $2,391,000 after purchasing an additional 538 shares in the last quarter. 85.86% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer.

See Also: Google Finance

Insider Buying and Selling by Quarter for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.